Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors
Phase 1/2
49
about 3.6 years
18+
3 sites in CT, FL, OK
About this study
This trial is testing the safety and side effects of a new drug combination called entinostat and ZEN003694 in people with advanced or resistant solid tumors. The goal is to find the best dose of this treatment.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take BET Bromodomain Inhibitor ZEN-3694
- 2.Take Entinostat
- 3.Undergo Computed Tomography
- +1 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Maximum tolerated dose (MTD) (Phase Ib), Objective response rate (ORR) (Phase II)
Secondary: Duration of response, Overall survival, Progression free survival, Response rate (RR) in patients with advanced/progressive pancreatic cancer (Phase II)
imaging, biopsy
Oncology